Underweight: Trim 30–40% over 3–4 weeks with AEP-calibrated put spread hedge and closing-basis stop at $402.24; reassess at Q3 2026 earnings
Underweight with $400 price target is consistent with the genuinely two-sided setup where the bear's $385 capitulation and the bull's $436 breakout are bracket boundaries, with $400 as central tendency assuming partial recovery with technical confirmation but not requiring full multiple re-rating to 22–23x. Do not initiate new longs absent a YoY margin recovery print. Pure Hold has destroyed alpha three times in eight sessions (2026-08-03 at -3.7%, 2026-08-05 at -2.0%, 2026-08-07 neutral at +0.4%). The 2026-07-31 Overweight generated -1.2% alpha with actively rolling MACD on a name with live regulatory overhangs — that lesson is directly applicable and rules out Buy/Overweight absent MACD bullish crossover and confirmed reclaims above 10 EMA.
| Position | Action |
|---|---|
| Position size | Trim 30–40% of UNH exposure over 3–4 weeks (not 2), retain smaller core position |
| Hedge sizing | $400/$365 put spread at 60–90 DTE, sized to 25% of residual position (not 33% as in 2026-08-06) tied to AEP-proximity (Q3 print mid-October ~8–10 weeks out) |
| Stop loss | Convert to CLOSING basis stop at $402.24 (lower Bollinger Band) to filter intraday volatility; only exit on confirmed close below with expanding volume |
| Trim pacing | Smaller initial tranches, scale up if price approaches $413–$420 resistance zone without breaking through |
| Optional overlay | Sell covered calls against residual at $425–$430 strikes expiring after Q2 print to offset hedge cost |
UNH at $408.74 offers a clean asymmetric setup: Q1 2026 EPS of $6.90 confirms the margin trough is behind, forward P/E of 18.2x trades below the S&P 500, and institutional accumulation plus a 5:1 reward-to-risk technical setup make buying now superior to waiting for confirmation.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 343.15 | bullish |
| close_50_sma | 412.83 | bearish |
| close_10_ema | 412.59 | bearish |
| macd | -1.86 | bearish |
| macds | +0.85 | bearish |
| macdh | -2.71 | bearish |
| rsi | 45.32 | neutral |
| boll (mid) | 419.25 | bearish |
| boll_ub | 436.26 | bearish |
| boll_lb | 402.24 | bearish |
| atr | 11.64 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price approaches $413–$420 resistance zone without breaking through
Then: Scale up trim tranches
Q1 2026 proves the margin trough is behind: EPS of $6.90 vs Q4 2025's $0.01, operating income up 19% sequentially, FCF rebounded to $8.15B from near-zero, with revenue still growing 11.8% YoY to $447.6B creating enormous EPS leverage as margins mean-revert
↩ rebuts: “Margin collapse narrative — Q1 2026 already shows recovery taking hold; Q4 2025 was the floor”
EV: +20.9% (to $494 target from $408.74 entry over 6–12 months) · concedes: The bear's HOLD instinct to avoid bottom-fishing wounded names is valid in general; Technical MACD and momentum signals are genuinely negative in the short term; Hormuz/oil macro risks are real for cyclical assets (though framed as a tailwind for defensives); Soft 2027 PBM guidance from CVS represents a legitimate near-term event risk for UNH; TTM earnings truly are the worst in three years due to $8.3B cyberattack charges and MLR spike
UNH at $408 is a SELL because the 69% earnings recovery is already priced into the 18.2x forward multiple, which represents a 30-90% premium to all managed-care peers; the technical setup shows distribution not accumulation; and the recovery thesis carries asymmetric downside risk from goodwill impairment and 2027 guidance misses.
· concedes: Credit given to bull for writing a 'clean essay'; Q1 2026 did show sequential improvement over Q4 2025; Some defensive bid may exist from macro uncertainty; Janus Henderson had a strong Q2 (+19%)
→ vs conservative: Conservative's defensive rotation thesis ignores that UNH is up 66.6% one-year; the trade has already moved, not pending. The 4.1% one-month return is the last flicker, not the first. Beta of 0.63 and Zacks defensive inclusion are lagging data points.
→ vs conservative: Conservative's Q1 2026 rebound narrative is mathematically misleading; Q1 2026 EPS of $6.90 vs Q1 2025 EPS of $6.85 is only 0.7% YoY growth. The Q4-to-Q1 sequential move is healthcare seasonality from deductible resets, not structural recovery. Conservative is anchoring on a misleading comparison.
→ vs conservative: Conservative's use of 200 SMA at 343 to justify long-term trend ignores that all short and medium-term indicators have rolled over. The 200 SMA is a lagging indicator that tells you where the stock has been, not where it's going. This creates a false sense of security.
→ vs neutral: Neutral's 'range-bound between 402 and 420' thesis is dangerous; RSI at 45 with MACD turning negative and price below both EMAs suggests breakdown is more likely than breakout. The lack of extreme readings provides false comfort rather than a contrarian buy signal.
→ vs neutral: Neutral's wait-and-see stance risks allowing a 5% pullback to become a 20% drawdown because there is no plan to act. The technical report itself flags that a clean break of 402.24 with volume would trigger a volatility-extension sell signal with targets at 395, 385, and 370.
| vwma | 417.62 | bearish |
Support: 402.24 | Resistance: 412.59 · 412.83 · 419.25 · 436.26
UNH is in a constructive long-term uptrend well above the 200 SMA but is currently consolidating beneath short- and medium-term averages with negative MACD momentum and a neutral RSI reading of 45.32. The lower Bollinger Band at 402.24 represents the critical support level to watch for a bearish breakdown, while a reclaim above 412.83 (50 SMA) would offer a tactical bullish entry trigger. The 20-day VWMA at 417.62 sits above current price, indicating volume-weighted conviction remains anchored at higher levels.
Market Cap
$371.2B
Share Price
~$408.93
52-Week High
$461.62
52-Week Low
$252.14
50-Day Avg
$412.80
200-Day Avg
$345.93
Beta
0.632
Dividend Yield
2.28%
P/E (TTM)
30.80x
Forward P/E
18.22x
PEG Ratio
1.25
P/B
3.54x
Revenue 2022
$324.2B
Revenue 2023
$371.6B
Revenue 2024
$400.3B
Revenue 2025
$447.6B
Gross Margin 2022
24.6%
Gross Margin 2025
18.5%
Operating Margin 2022
8.8%
Operating Margin 2025
4.2%
Net Income 2023
$22.38B
Net Income 2025
$12.06B
Diluted EPS 2023
$23.86
Diluted EPS 2025
$13.23
Q1 2025 Revenue
$109.58B
Q1 2025 Operating Income
$9.12B
Q1 2025 Net Income
$6.29B
Q1 2025 EPS
$6.85
Q4 2025 Revenue
$113.22B
Q4 2025 Operating Income
$0.38B
Q4 2025 Net Income
$0.01B
Q4 2025 EPS
$0.01
Q1 2026 Revenue
$111.72B
Q1 2026 Operating Income
$8.99B
Q1 2026 Net Income
$6.28B
Q1 2026 EPS
$6.90
Operating Cash Flow 2022
$26.21B
Operating Cash Flow 2023
$29.07B
Operating Cash Flow 2025
$19.70B
Free Cash Flow 2023
$25.68B
Free Cash Flow 2025
$16.08B
Q1 2026 Free Cash Flow
$8.15B
Dividends Paid 2022
$5.99B
Dividends Paid 2025
$7.92B
Buybacks 2025
$5.55B
Total Debt Q1 2026
$77.9B
Cash & Equivalents Q1 2026
$28.0B
Net Debt Q1 2026
$49.9B
Goodwill Q1 2026
$130.6B
Tangible Book Value Q1 2026
-$32.7B
Working Capital Q1 2026
-$23.0B
Current Ratio Q1 2026
0.80
Profit Margin TTM
3.14%
Operating Margin TTM
7.13%
Return on Equity
14.15%
Return on Assets
4.38%
EPS TTM
$13.27
Forward EPS
$22.44
Revenue TTM
$450.1B
Net Income TTM
$14.1B
FCF TTM
$22.8B
Effective Tax Rate 2025
12.9%
Strengths
Concerns
UnitedHealth Group faces a critical recovery phase after a severe earnings contraction driven by elevated medical costs, Medicare Advantage pressures, and the Change Healthcare cyberattack. While Q1 2026 EPS of $6.90 demonstrates early recovery, revenue of $447.6B in 2025 generated only $12.06B in net income (3.14% margin) versus $22.38B in 2023. The balance sheet shows $77.9B in debt against $28.0B cash with negative tangible book value, though net debt is declining. Forward P/E of 18.2x versus TTM P/E of 30.8x reflects consensus expectations for a 69% EPS rebound to $22.44, but this recovery remains uncertain given repeated downside surprises. Capital return via buybacks is paused, though the 2.28% dividend with 5% CAGR growth is intact. The key catalyst will be Q2 2026 earnings (expected mid-July) confirming whether the Q1 recovery is sustained or a one-quarter anomaly.
Macro: The macro backdrop is mixed but broadly supportive for defensives: Polymarket prices 86% probability of no Fed rate cuts in 2026 (up +3.2pp week-over-week), while US recession risk by end-2026 sits at just 8%, supporting a soft-landing thesis. However, geopolitical risks dominate: Hormuz reopening hopes have sharply faded (near-dated contract probabilities down 10+pp w/w), driving crude higher and Treasury yields higher, with the S&P 500 retreating from records and the Dow breaking its winning streak. The Nasdaq-leading tape on chip-stock rebound suggests brief rotation away from defensives, though UNH's recent +4% one-month return indicates the defensive bid is holding.